Sunshine Biopharma Inc
NASDAQ:SBFM
Sunshine Biopharma Inc
Inventory
Sunshine Biopharma Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
Inventory
$14.1m
|
CAGR 3-Years
273%
|
CAGR 5-Years
252%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Inventory
$44.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's Inventory?
Inventory
14.1m
USD
Based on the financial report for Sep 30, 2025, Sunshine Biopharma Inc's Inventory amounts to 14.1m USD.
What is Sunshine Biopharma Inc's Inventory growth rate?
Inventory CAGR 5Y
252%
Over the last year, the Inventory growth was 43%. The average annual Inventory growth rates for Sunshine Biopharma Inc have been 273% over the past three years , 252% over the past five years .
